Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lumakras (sotorasib) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• The pooled Objective Response Rate (ORR) for KRAS^G12C inhibitors (sotorasib and adagrasib) in patients with KRAS^G12C-mutated solid tumors was 31% (95% CI, 25-37%).
• The pooled Disease Control Rate (DCR) for KRAS^G12C inhibitors was 86% (95% CI, 82-89%).
• In KRAS^G12C-mutated NSCLC patients with a KEAP1 co-mutation, the ORR was significantly lower (OR: 0.35, 95% CI: 0.16-0.77) compared to those with wild-type KEAP1.
• The pooled incidence rate of grade ≥3 adverse events (AEs) for KRAS^G12C inhibitors in patients with KRAS^G12C-mutated solid tumors was 29% (95% CI, 23-36%).
• The population included 1224 patients with KRAS^G12C-mutated solid tumors, with a specific focus on NSCLC patients having a KEAP1 co-mutation; this subgroup exhibited a significantly worse ORR (OR: 0.35, 95% CI: 0.16-0.77) compared to those with wild-type KEAP1, indicating a potentially inferior therapeutic outcome.